Navidea Biopharmaceuticals (NYSE:NAVB) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a report released on Friday. The brokerage set a “sell” rating on the stock.

Navidea Biopharmaceuticals Price Performance

NAVB stock opened at $0.00 on Friday. Navidea Biopharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.13. The company has a market cap of $100,084.00, a PE ratio of -0.02 and a beta of 1.45.

Navidea Biopharmaceuticals Company Profile

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.